U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216391) titled 'Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG' on Sept. 22.
Brief Summary: This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will be followed for 12 months after administration.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Type 1 Diabetes Mellitus
Intervention:
DRUG: Antithymocyte Globulin (ATG)
Thymoglobulin
DRUG: Teplizumab
Intravenous infusions of teplizumab given for 14 consecuti...